Physician profile
Paul Ky
NPI 1043374028
$30,223.13
in general payments reported to CMS, 2019-2025
46 companies · $2,707 in 2025
The $2,707 reported for 2025 was more than what 83% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,635 · 2020: $2,166 · 2021: $9,779 · 2022: $3,395 · 2023: $4,276 · 2024: $6,265 · 2025: $2,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,747.98 |
| Consulting Fee | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nutech Spine, INC. | $7,446.43 | 2021 | |
| Boston Scientific Corporation | $4,669.59 | 2019-2025 | Wavewriter Alpha Prime 16, Fixate, Infinion 16 |
| Abbott Laboratories | $3,619.68 | 2019-2025 | Proclaim, Eterna, Octrode |
| Orthofundamentals, LLC | $2,500.00 | 2024 | |
| Nevro Corp. | $2,369.62 | 2019-2024 | Senza |
| Vertos Medical, INC. | $1,391.87 | 2019-2024 | Mild Device Kit |
| Relievant Medsystems, INC. | $1,372.92 | 2021-2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,069.99 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $1,056.77 | 2019-2025 | Xtampza, Belbuca |
| Curonix LLC | $794.20 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $719.94 | 2021-2025 | |
| Painteq LLC | $480.50 | 2021-2023 | Painteq |
| Globus Medical, INC. | $272.77 | 2025 | Omnia, Senza |
| Nalu Medical, INC. | $239.74 | 2021-2024 | Nalu Neurostimulation System |
| Vertiflex, INC. | $222.46 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.